ARIAD Pharmaceuticals Inc. and Gen Ilac announced that ARIAD has granted Gen Ilac exclusive rights to distribute Iclusig® (ponatinib) in Turkey for patients with Philadelphia-positive leukemias. Gen Ilac was granted the exclusive right to sell Iclusig as an investigational product in Turkey on a named-patient basis and will provide associated medical affairs and regulatory support. ARIAD retains the option to file for marketing authorization at a later date and, if approved, to hold the Marketing Authorization for Iclusig in Turkey.

Gen Ilac has the exclusive right then to market and commercialize the product upon approval.